The month-long standoff between the US Health Resources and Services Administration (HRSA) and Johnson & Johnson came to an ...

UCB taps new UK head. Belgium-based global biopharmaceutical company UCB welcomed Nico Reynders as its new general manager ...

As has been widely acknowledged, one of the most meaningful steps a business can take is to establish a single point of ...

South Korea has designated life sciences and biotechnology as priority areas for growth and leadership. The country is experiencing rapid growth in biotechnology thanks to continuous public and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Empathy is the ability to emotionally understand what other people feel, see things from their point of view, and imagine yourself in their shoes. It’s a fundamental aspect of any successful ...

The UK is currently amid negotiations on a new voluntary scheme, due to start in 2024, that sets out the framework for pricing and access to branded treatments. If it can be agreed, this will be a ...

This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic. 2024 will inherit the challenges of 2023 and see ...

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category. The deal, which has a top ...

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a shareholder lawsuit that ...

Recent studies have revealed that many UK families are unable to engage in today's digital society due to a lack of online skills and access to devices, data, and broadband. While this may seem ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...